Repros Therapeutics Inc. (Nasdaq: RPRX) today reported top-line results for the first pivotal study of Androxal, ZA-301, in the treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE